A Targeted Literature Search and Phenomenological Review of Perspectives of People with Multiple Sclerosis and Healthcare Professionals of the Immunology of Disease-Modifying Therapies-Reference-Cited by-同舟云学术

A Targeted Literature Search and Phenomenological Review of Perspectives of People with Multiple Sclerosis and Healthcare Professionals of the Immunology of Disease-Modifying Therapies

Published:2022-05-24 Issue:3 Volume:11 Page:955-979
ISSN:2193-8253
Container-title:Neurology and Therapy
language:en
Short-container-title:Neurol Ther

Author:

Burtchell Jeri,Clemmons Daisy,Clemmons Joann,Sabutis Tim,Rosenberg Adeline,Graves Jennifer,Sweeney Michael L.,Kramer John,Ziehn Marina,Brown Brandon,Weiss Jamie L.,Obeidat Ahmed Z.

Funder

Novartis Pharmaceuticals Corporation

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

https://link.springer.com/content/pdf/10.1007/s40120-022-00349-5.pdf

Reference70 articles.

1. Stankiewicz JM, Weiner HL. An argument for broad use of high efficacy treatments in early multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2020;7:e636.

2. Bayas A. Improving adherence to injectable disease-modifying drugs in multiple sclerosis. Expert Opin Drug Deliv. 2013;10:285–7.

3. Multiple Sclerosis International Federation. Atlas of MS. 2013. http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf. Accessed 09 Feb 2022

4. Wallin MT, Culpepper WJ, Campbell JD, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. 2019;92:e1029–40.

5. Greenfield AL, Hauser SL. B-cell therapy for multiple sclerosis: entering an era. Ann Neurol. 2018;83:13–26.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preferences for neuromyelitis optica spectrum disorder treatments: A conjoint analysis with neurologists in Spain;Multiple Sclerosis and Related Disorders;2024-08

2. De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate;Advances in Therapy;2024-06-11

3. Examining the Type, Quality, and Content of Web-Based Information for People With Chronic Pain Interested in Spinal Cord Stimulation: Social Listening Study;Journal of Medical Internet Research;2024-01-30

4. Examining the Type, Quality, and Content of Web-Based Information for People With Chronic Pain Interested in Spinal Cord Stimulation: Social Listening Study (Preprint);2023-04-29